Caris Life Sciences (NASDAQ:CAI) Stock Price Down 7.7% – Should You Sell?

Caris Life Sciences, Inc. (NASDAQ:CAI)’s share price fell 7.7% during trading on Friday . The stock traded as low as $19.23 and last traded at $19.24. 1,037,905 shares traded hands during mid-day trading, a decline of 56% from the average session volume of 2,385,899 shares. The stock had previously closed at $20.85.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on CAI shares. Wall Street Zen upgraded shares of Caris Life Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Caris Life Sciences in a report on Monday, December 29th. Evercore set a $38.00 target price on shares of Caris Life Sciences in a research note on Monday, January 5th. Canaccord Genuity Group increased their price target on shares of Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Monday, December 22nd. Finally, Robert W. Baird initiated coverage on shares of Caris Life Sciences in a research note on Tuesday. They set an “outperform” rating and a $26.00 price target for the company. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Caris Life Sciences presently has an average rating of “Hold” and an average price target of $31.33.

Caris Life Sciences Price Performance

The stock has a market capitalization of $5.51 billion and a PE ratio of -42.46. The business has a 50 day moving average price of $25.44. The company has a quick ratio of 9.36, a current ratio of 9.93 and a debt-to-equity ratio of 0.79.

Insider Buying and Selling

In related news, insider Luke Thomas Power sold 62,250 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the completion of the sale, the insider directly owned 99,571 shares of the company’s stock, valued at $2,646,597.18. This trade represents a 38.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.80% of the stock is currently owned by company insiders.

Institutional Trading of Caris Life Sciences

Large investors have recently made changes to their positions in the business. Global Retirement Partners LLC raised its holdings in shares of Caris Life Sciences by 99,900.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after buying an additional 999 shares during the last quarter. Olistico Wealth LLC acquired a new stake in Caris Life Sciences in the 4th quarter valued at about $31,000. MetLife Investment Management LLC raised its stake in shares of Caris Life Sciences by 84.0% in the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock worth $45,000 after acquiring an additional 755 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new position in shares of Caris Life Sciences in the fourth quarter worth about $67,000. Finally, Federated Hermes Inc. acquired a new position in shares of Caris Life Sciences during the fourth quarter worth approximately $81,000.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.